Ovid Therapeutics is a biotechnology business based in the US. Ovid Therapeutics shares (OVID) are listed on the NASDAQ and all prices are listed in US Dollars. Ovid Therapeutics employs 40 staff and has a trailing 12-month revenue of around $473,695.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.06 |
|---|---|
| 52-week range | $0.68 - $4.14 |
| 50-day moving average | $1.97 |
| 200-day moving average | $2.98 |
| Wall St. target price | $3.03 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.72 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.06 from 2024-07-25
| 1 week (2024-07-19) | 3.92% |
|---|---|
| 1 month (2024-06-27) | 45.93% |
| 3 months (2024-04-26) | -65.81% |
| 6 months (2024-01-26) | -71.51% |
| 1 year (2023-07-27) | -69.50% |
|---|---|
| 2 years (2022-07-27) | -48.79% |
| 3 years (2021-07-27) | 3.73 |
| 5 years (2019-07-26) | 2.12 |
| Revenue TTM | $473,695 |
|---|---|
| Gross profit TTM | $1.5 million |
| Return on assets TTM | -28.09% |
| Return on equity TTM | -50.87% |
| Profit margin | 0% |
| Book value | $1.11 |
| Market Capitalization | $72.4 million |
TTM: trailing 12 months
We're not expecting Ovid Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Ovid Therapeutics's shares have ranged in value from as little as $0.68 up to $4.1389. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ovid Therapeutics's is 0.435. This would suggest that Ovid Therapeutics's shares are less volatile than average (for this exchange).
Ovid Therapeutics Inc. , a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.